Mon, 19 Oct 2020 14:30:47: Intellia to kickstart first single-course ‘curative’ CRISPR shot, as it hopes to beat rivals Alnylam, Ionis and Pfizer

Mon, 19 Oct 2020 12:41:39: Breast cancer study uncovers new RNA targets for treatment and diagnostics

Mon, 19 Oct 2020 12:28:41: Kite's former EU chief Nowers joins NK cell startup ONK as CEO

Mon, 19 Oct 2020 08:52:07: Evotec nabs Gates Foundation cash for low-income country COVID-19 antibody work

Fri, 16 Oct 2020 12:02:09: Eli Lilly strikes deal to sell R&D campus to UCB

Fri, 16 Oct 2020 07:48:50: Galapagos' osteoarthritis drug flunks phase 2, dashing hopes of $250M Gilead deal

Fri, 16 Oct 2020 02:37:36: Chutes & Ladders—Biogen veteran Ong joins Flagship Pioneering as CEO-partner

Thu, 15 Oct 2020 15:57:59: Tackling multiple sclerosis with a plant sugar

Thu, 15 Oct 2020 14:01:13: After R&D tryout, Astellas opts to acquire bioelectronics maker Iota Biosciences in $304M deal

Thu, 15 Oct 2020 13:50:02: COVID-19 mRNA vaccine candidate from Sanofi and Translate protects mice, monkeys: study

Thu, 15 Oct 2020 12:32:25: Sage shares data on retreatment with depression drug zuranolone

Thu, 15 Oct 2020 10:39:20: Otsuka's guadecitabine flunks 2 more late-phase cancer trials

Wed, 14 Oct 2020 12:19:40: Cyclerion fails sickle cell test, prompting pivot to CNS disease

Wed, 14 Oct 2020 10:26:00: Ong leaves Biogen to become CEO-partner at Flagship

Wed, 14 Oct 2020 08:56:22: Large genomics study points the way to future cancer clinical trials

Wed, 14 Oct 2020 00:33:54: Dyno, Roche to tackle CNS, liver disease in gene therapy deal worth up to $1.8B

Tue, 13 Oct 2020 15:47:47: RayzeBio debuts with $45M to target tumors with radiopharmaceuticals

Tue, 13 Oct 2020 12:09:56: Gossamer Bio's DP2 inhibitor GB001 fails 2 midphase trials

Tue, 13 Oct 2020 10:47:13: EdiGene raises $67M to take gene-editing therapies into humans

Mon, 12 Oct 2020 12:25:54: Wasp toxin inspires new antibiotic that overcomes tough-to-treat sepsis in mice

Mon, 12 Oct 2020 12:19:03: Priothera raises €30M to trial ex-Novartis' S1P drug in AML

Mon, 12 Oct 2020 10:05:55: AstraZeneca gets $486M to test if COVID-19 antibodies can provide 12 months of protection

Fri, 09 Oct 2020 13:21:32: Stopping COVID-19 by targeting out-of-control immune cells

Fri, 09 Oct 2020 12:33:39: Sensei raises $29M to advance anti-cancer bacteriophage pipeline

Fri, 09 Oct 2020 12:01:30: Fauci weighs in on Regeneron's Trump-backed COVID-19 drug: 'Good chance' it helped him